Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines - PubMed (original) (raw)
Comparative Study
doi: 10.1677/erc.1.00899.
Affiliations
- PMID: 15788640
- DOI: 10.1677/erc.1.00899
Comparative Study
Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines
J A Vendrell et al. Endocr Relat Cancer. 2005 Mar.
Abstract
The aim of this study was to explore the pharmacological response to 4-hydroxy-tamoxifen (OH-Tam) and to estradiol (E2) in three cell lines: MVLN, a human breast carcinoma cell line derived from MCF-7, and two MVLN-derived OH-Tam-resistant (OTR) cell lines, called CL6.8 and CL6.32. The OH-Tam response in the OTR cells was associated with the development of both an agonist activity of the drug on cell proliferation and the resistance of the cells to OH-Tam-induced apoptosis. The OTR cells also developed an increased sensitivity to the E2 growth-stimulating activity. To delineate the genes that determine such responses, we combined a mini-array-based gene-selection approach and an extensive real-time quantitative PCR exploration in the MVLN and OTR cell lines exposed to three pharmacological conditions: a 4-day treatment with E2, OH-Tam or both E2 and OH-Tam. Compiled data revealed a hyper-response to E2 and a modification of the OH-Tam pharmacological response (loss of antagonist action and agonist activity) at the gene-expression level. The proteins encoded by the genes selected in this study have been reported to be involved in the regulation of cell proliferation, cell transformation, DNA repair and apoptosis, or belong to the ErbB/epidermal growth factor receptor-driven pathway. Our data also provide evidence of changes in transcriptional co-regulator expression, elevated mitogen-activated protein kinase activity and increase in the phosphorylation status of estrogen receptor alpha on serine residue 118 in the OTR cell lines, suggesting the possible involvement of such mechanisms in the agonist activity of OH-Tam and/or the hyper-response of cells to E2. Taken together, our study should enhance our knowledge of the multifactorial events associated with the development of Tam resistance in two independent cell lines issued from the same selection process and should help in the identification of potential molecular targets for diagnosis or therapy.
Similar articles
- Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC. Yao K, et al. Clin Cancer Res. 2000 May;6(5):2028-36. Clin Cancer Res. 2000. PMID: 10815929 - Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R, Tanabe K, Emi M, Uchida Y, Osaki A, Toge T. Kim R, et al. Int J Oncol. 2005 Apr;26(4):1025-31. Int J Oncol. 2005. PMID: 15753998 - Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC. Johnston SR, et al. Clin Cancer Res. 1999 Feb;5(2):251-6. Clin Cancer Res. 1999. PMID: 10037172 - [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F. Bachmann-Moisson N, et al. Bull Cancer. 1996 Oct;83(10):808-15. Bull Cancer. 1996. PMID: 8952630 Review. French. - Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review).
Toma S, Ugolini D, Palumbo R. Toma S, et al. Int J Oncol. 1999 Aug;15(2):321-37. Int J Oncol. 1999. PMID: 10402244 Review.
Cited by
- Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer.
Caldon CE, Musgrove EA. Caldon CE, et al. Cell Div. 2010 Jan 17;5:2. doi: 10.1186/1747-1028-5-2. Cell Div. 2010. PMID: 20180967 Free PMC article. - mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels.
Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C, Cohen PA. Ghayad SE, et al. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x. Cancer Sci. 2008. PMID: 19016759 Free PMC article. - New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines.
Crowe DL, Lee MK. Crowe DL, et al. Breast Cancer Res. 2006;8(1):R1. doi: 10.1186/bcr1362. Epub 2005 Dec 9. Breast Cancer Res. 2006. PMID: 16417649 Free PMC article. - Headway in resistance to endocrine therapy in breast cancer.
Xu Y, Sun Q. Xu Y, et al. J Thorac Dis. 2010 Sep;2(3):171-7. doi: 10.3978/j.issn.2072-1439.2010.02.03.9. J Thorac Dis. 2010. PMID: 22263039 Free PMC article. - A role for estrogen receptor phosphorylation in the resistance to tamoxifen.
de Leeuw R, Neefjes J, Michalides R. de Leeuw R, et al. Int J Breast Cancer. 2011;2011:232435. doi: 10.4061/2011/232435. Epub 2011 Jul 12. Int J Breast Cancer. 2011. PMID: 22295213 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous